Hikma Pharmaceuticals Expands Portfolio with Novugen's Trametinib ANDA Acquisition Hikma Pharmaceuticals has successfully acquired Novugen's FDA-approved ANDA for trametinib, enhancing its portfolio in oncology treatments.

Hikma Pharmaceuticals Expands Portfolio with Novugen's Trametinib ANDA Acquisition #London #United_Kingdom #Hikma_Pharmaceuticals #Novugen #trametinib